PeDRA 2026: Nemolizumab Phase II Data Show Long — Term Symptom Relief for Children Aged 2 to 11 Years With Moderate — to — Severe Atopic Dermatitis
For best results when printing this announcement, please click on link below: PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderat